IDM, Sanofi-Synthélabo Enter Deal Potentially Worth $545M

PARIS Immuno-Designed Molecules SA, a Paris-based company specialized in the development of cellular immunotherapies for cancer, signed a co-development agreement with the French pharmaceutical company Sanofi-Synthélabo SA covering the whole range of IDMs cell drugs for cancer.